Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression
Open accessThe DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Abstract
Psilocybin shows efficacy to alleviate depression in human clinical trials for six or more months after only one or two treatments. Another hallucinogenic drug, esketamine, has recently been U.S. Food and Drug Administration (FDA)-approved as a rapid-acting antidepressant. The mechanistic basis for the antidepressant effects of psilocybin and ketamine appear to be conserved. The efficacy of these two medications has not, however, been directly compared either clinically or preclinically. Further, whether or not a profound subjective existential experience is necessary for psilocybin to have antidepressant effects is unknown. To address these questions, we tested psilocybin, lysergic acid diethylamide (LSD), and ketamine in a rat model for depression. As in humans, a single administration of psilocybin or LSD produced persistent antidepressant-like effects in our model. In contrast, ketamine produced only a transient antidepressant-like effect. Our results indicate that classic psychedelics may have therapeutic efficacy that is more persistent than that of ketamine, and also suggest that a subjective existential experience may not be necessary for therapeutic effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ketamine's effects on structural plasticity appear to last for approximately a week (150) while psilocybin's effects seem to be more durable lasting for at least a month (151, 152)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [151]
In the citing paper
“This may explain why they have demonstrated efficacy in many preclinical rodent behavioral tests involving PFC circuitry including the forced swim test and fear extinction learning (151, 194–197).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [151]
In the citing paper
“the mood-elevating properties of psilocybin seem to last significantly longer”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [151]
Citations
Cites
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
The use of the elevated plus maze as an assay of anxiety-related behavior in rodents
Walf, A. A., & Frye, C. A. (2007) · Nature Protocols · doi:10.1038/nprot.2007.44 · Cited by 3,035
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Using the rat forced swim test to assess antidepressant-like activity in rodents
Slattery, D. A., & Cryan, J. F. (2012) · Nature Protocols · doi:10.1038/nprot.2012.044 · Cited by 903
Research works printed but not linked: 3
- Russell, 2009, The three Rs and the humanity criterion
- Hibicke, M. (2017) Development and Evaluation of an Adolescent Chronic Restraint Stress (ACRS) Protocol to Model Adult Depression in Female Rats. Ph.D. Thesis, Mercer University.
- Sengupta, 2013, The Laboratory Rat: Relating Its Age With Human’s, Int. J. Prev. Med., 4, 624
Cited by
The subjective effects of psychedelics are necessary for their enduring therapeutic effects
Yaden, D. B., & Griffiths, R. R. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00194 · Cited by 541
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01316-5 · Cited by 478
Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B., & Thompson, S. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022489118 · Cited by 378
“Although psilocybin has been reported to have delayed antidepressant-like effects in the forced swim test in some, but not all, strains of rats (13, 33), we were unable to replicate this finding in mice.”
BackgroundMethodInfluentialThe neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 302
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
De Gregorio, D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 259
“…(1mg/kg) then tested in the forced swim test at various time points between 1 and 5 weeks after administration, and in the elevated plus maze 6 weeks after administration, develop distinct behavioral responses depending on when they first encounter the forced swim test (Hibicke et al., 2020).”
InfluentialSelf-citationPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109836 · Cited by 224
“Notably, it has been suggested that a single administration of psilocybin or LSD produces long-lasting (for 5 weeks postadministration) antidepressant-like effects in rats within models of behavioral despair or passivity such as the forced swim test (Hibicke et al., 2020).”
InfluentialModels of psychedelic drug action: modulation of cortical-subcortical circuits
Doss, M. K., Madden, M. B., Gaddis, A., Nebel, M. B., Griffiths, R. R., Mathur, B. N., & Barrett, F. S. (2022) · Brain · doi:10.1093/brain/awab406 · Cited by 199
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
A non-hallucinogenic LSD analog with therapeutic potential for mood disorders
Lewis, V., Bonniwell, E. M., Lanham, J. K., Ghaffari, A., Sheshbaradaran, H., Cao, A. B., Calkins, M. M., Bautista-Carro, M. A., Arsenault, E., Telfer, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112203 · Cited by 165
“5,6 Psychedelics such as psilocybin, N,N -dimethyltryptamine (DMT), and (+)-ly- sergic acid diethylamide (LSD) can induce mystical states and profound alterations of consciousness, effects that are largely mediated by serotonin 2A (5-HT 2A ) receptor activation.”
BackgroundBiochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 129
De Gregorio, D., Popic, J., Enns, J. P., Inserra, A., Skalecka, A., Markopoulos, A., Posa, L., Lopez-Canul, M., He, Q., Lafferty, C. K., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020705118 · Cited by 139
“Unlike ketamine, we found that LSD does not have antidepressant properties in naïve mice, in contrast to recent work showing that LSD at 150 μg/kg produced antidepressant-like effects 5 wk after a single administration (35).”
Depression: Biological markers and treatment
Nedic Erjavec, G., Sagud, M., Nikolac Perkovic, M., Svob Strac, D., Konjevod, M., Tudor, L., Uzun, S., & Pivac, N. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110139 · Cited by 119
5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines
Cameron, L. P., Patel, S. D., Vargas, M. V., Barragan, E. V., Saeger, H. N., Warren, H. T., Chow, W. L., Gray, J. A., & Olson, D. E. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00718 · Cited by 118
Jefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959614 · Cited by 127
“First, the translationally relevant dose (in rodents) for the putative therapeutic effects of psilocybin is yet to be fully established (Hibicke and Nichols, 2020; Hibicke et al., 2020; Jefsen et al., 2019; Meinhardt et al., 2020).”
BackgroundMolecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
“In addition, the role of the psychedelic experience in mediating antidepressant effects is unknown [34, 35].”
BackgroundMcCulloch, D. E.-W., Grzywacz, M. Z., Madsen, M. K., Jensen, P. S., Ozenne, B., Armand, S., Knudsen, G. M., Fisher, P. M., & Stenbæk, D. S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841648 · Cited by 126
Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth
Ly, C., Greb, A. C., Vargas, M. V., Duim, W. C., Grodzki, A. C. G., Lein, P. J., & Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00065 · Cited by 123
Wojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Szych, Z., Majcher‐Maślanka, I., Herian, M., Maćkowiak, M., & Gołembiowska, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126713 · Cited by 119
“…performed 24 h after the administration of the drugs, and while that is enough to eliminate their acute effects, it might not be enough for the long-lasting effects to manifest fully, as Hibicke et al. (2020) [26] reported an antidepressant effect observed 7 days post psilocybin administration.”
BackgroundErkizia-Santamaría, I., Alles-Pascual, R., Horrillo, I., Meana, J. J., & Ortega, J. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113612 · Cited by 119
Zanos, P., Brown, K. A., Georgiou, P., Yuan, P., Zarate, C. A., Thompson, S. M., & Gould, T. D. (2023) · The Journal of Neuroscience · doi:10.1523/jneurosci.1316-22.2022 · Cited by 115
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 81
Gregorio, D. D., Inserra, A., Enns, J. P., Markopoulos, A., Pileggi, M., Rahimy, Y. E., López-Canul, M., Comai, S., & Gobbi, G. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01301-9 · Cited by 101
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
“Selective” serotonin 5-HT2A receptor antagonists
Casey, A. B., Cui, M., Booth, R. G., & Canal, C. E. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115028 · Cited by 96
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 85
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 79
“…adaptive circuits (e.g., cortical spinogenesis [80]) are directly coupled and virtually synonymous with therapeutic behavioral changes, as no additional integration-like process is modeled in studies which show antidepressant-like effects of psychedelic compounds [49, 51, 54, 114, 133, 216, 217].”
BackgroundResultPsychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
“Psilocybin has been shown to promote fear extinction in mice (Catlow et al., 2013), and produce long- lasting antidepressant- like effects in rats subjected to the forced swim test (Hibicke et al., 2020).”
BackgroundPsilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
Zhao, X., Du, Y., Yao, Y., Dai, W., Yin, Y., Wang, G., Li, Y., & Zhang, L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249436 · Cited by 71
“Surprisingly, a study showed that psilocybin may have therapeutic efficacy that is more persistent than that of ketamine (Hibicke et al., 2020).”
BackgroundPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“In the same study, psilocybin decreased immobility in the FST for up to 5 weeks after administration compared to control rats, whereas ketamine injected rats displayed decreased immobility up to 2 weeks, suggesting a longer lasting therapeutic effect of psilocybin over ketamine (132).”
BackgroundInfluentialClinically relevant acute subjective effects of psychedelics beyond mystical experience
Yaden, D. B., Goldy, S. P., Weiss, B., & Griffiths, R. R. (2024) · Nature Reviews Psychology · doi:10.1038/s44159-024-00345-6 · Cited by 71
“Although experiences involving ‘existential’ meanings are of course unlikely to be present in rodent models 59 , an array of subjective experiences might be shared across mammalian species (without any linguistic element) including feelings of attachment, approach orientation, social engagement,…”
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
Meinhardt, M. W., Güngör, C., Skorodumov, I., Mertens, L. J., & Spanagel, R. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0694-z · Cited by 65
Chen, T., Cheng, L., Ma, J., Yuan, J., Pi, C., Xiong, L., Chen, J., Liu, H., Tang, J., Zhong, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106837 · Cited by 52
Psychosis and psychedelics: Historical entanglements and contemporary contrasts
Friesen, P. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221129116 · Cited by 61
“There is debate about whether it counts as a psychedelic, and it is sometimes described as an anti-depressant, a psychotomimetic, or both at once (Hibicke et al., 2020; Ye et al., 2019).”
BackgroundTransient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice
Jones, N., Zahid, Z., Grady, S. M., Sultan, Z. W., Zheng, Z., Razidlo, J. A., Banks, M. I., & Wenthur, C. J. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00123 · Cited by 61
Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Jaster, A. M., & González‐Maeso, J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02274-x · Cited by 61
“…that psychedelics promote escape-related behaviors in the forced swim test (shown as decreased immobility and increased swimming and/or climbing), and reduce fear extinction learning or fear expression through mechanisms dependent, at least in part, on 5-HT 2A receptor activation [215 – 217 , 234].”
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 57
“Indeed, by activating the TrkB receptor, mTOR and 5-HT2A signalling pathways in the prefrontal cortex, it produced an increase in dendritic arbor complexity, promote dendritic spine growth, and stimulate synapse formation, thus revealing a fast-acting, robust and persistent antidepressant effect [170,238].”
BackgroundTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
Revenga, M. D. L. F., Jaster, A. M., McGinn, J., Silva, G. M., Saha, S., & González‐Maeso, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00170 · Cited by 56
dos Santos, R. G., Hallak, J. E., Baker, G., & Dursun, S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986422 · Cited by 55
“Antidepressant-like actions were reported in rodents after administration of the 5-HT2A agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) (Masuda and Sugiyama, 2000), LSD (Buchborn et al., 2014; Hibicke et al., 2020), psilocybin (Hibicke et al., 2020), and DMT (Cameron et al., 2018, 2019).”
BackgroundInfluentialEffinger, D. P., Quadir, S. G., Ramage, M. C., Cone, M. G., & Herman, M. A. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02414-5 · Cited by 55
“These findings lend to recent studies in both clinical [11, 13, 65] and preclinical [66] literature showing persistent reductions in depressive behavior after a single dose of psilocybin.”
ResultIsolation of psychedelic-responsive neurons underlying anxiolytic behavioral states
Muir, J., Lin, S., Aarrestad, I. K., Daniels, H. R., Ma, J., Tian, L., Olson, D. E., & Kim, C. K. (2024) · Science · doi:10.1126/science.adl0666 · Cited by 55
Rijsketic, D. R., Casey, A. B., Barbosa, D. A. N., Zhang, X., Hietamies, T. M., Ramirez-Ovalle, G., Pomrenze, M. B., Halpern, C. H., Williams, L. M., Malenka, R. C., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01613-4 · Cited by 53
“…our demonstration that TRAP2 mice can be used to genetically label neural ensembles activated by psilocybin provides a potential platform for determining the networks and cell types that mediate psilocybin ’ s therapeutic-like effects and whether these effects are context-or state-dependent.”
BackgroundWolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 52
“Notably, using models of behavioral despair or passivity such as the forced swim test, it has been suggested that a single administration of psilocybin or LSD produced long-lasting (up to 5 weeks) antidepressant-like effects in rats [161].”
BackgroundMethodPsilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice
Thomas, C. W., Blanco‐Duque, C., Bréant, B. J. B., Goodwin, G. M., Sharp, T., Bannerman, D. M., & Vyazovskiy, V. V. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01846-9 · Cited by 52
“While the evidence demonstrates that psychedelics can induce structural and functional synaptic plasticity in vivo [27–29], facilitate learning and memory [30–32], and exert long-lasting behavioural effects [33, 34] in rodents, the specific underlying neurophysiology remains unclear, especially regarding the relevance…”
BackgroundMolecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
Tuck, J. R., Dunlap, L. E., Khatib, Y. A., Hatzipantelis, C. J., Novak, S. W., Rahn, R. M., Davis, A. R., Mosswood, A., Vernier, A. M. M., Fenton, E. M., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416106122 · Cited by 50
“In fact, 5 - HT2A receptor agonists have been shown to produce antidepressant effects in both rodents ( 71 – 74 ) and humans ( 75 , 76 , 77 ), and recent evidence suggests that LSD may have procognitive effects ( 78 ).”
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 47
“However, the effects of ketamine are not as persistent as those observed with classical psychedelics [18], which can persist for months or even years after just one or two dosing sessions [7, 19 – 22].”
Strumila, R., Nobile, B., Korsakova, L., Lengvenytė, A., Olié, É., López‐Castromán, J., Guillaume, S., & Courtet, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121213 · Cited by 48
Inserra, A., Campanale, A., Cheishvili, D., Dymov, S., Wong, A. H. Y., Marçal, N., Syme, R. A., Taylor, L., Gregorio, D. D., Kennedy, T. E., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110594 · Cited by 47
Sałaciak, K., & Pytka, K. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107872 · Cited by 46
Trunnell, E. R., Baines, J., Farghali, S., Jackson, T. A., Jayne, K., Smith, R., & Stibbe, T. (2024) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2024.105666 · Cited by 45
Kelley, D. P., Venable, K., Destouni, A., Billac, G., Ebenezer, P., Stadler, K., Nichols, C., Barker, S., & Francis, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00660 · Cited by 42
Self-citationBraun, D., Rosenberg, A. M., Rabaniam, E., Haruvi, R., Malamud, D., Barbara, R., Aiznkot, T., Levavi‐Sivan, B., & Kawashima, T. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02391-7 · Cited by 41
“These reported therapeutic effects are markedly different from the short-lasting effects of other classes of psychedelics such as ketamine [11], making psilocybin and its derivatives a promising class of drugs for treating mood-related disorders.”
BackgroundWulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 42
“A single administration of psilocybin or LSD in male Wistar-Kyoto rats produced long-lasting effects and persistently reduced immobility time in the FST seven to 35 days after treatment and increased time spent in open arms on the elevated plus maze 41 days after treatment (Hibicke et al., 2020).”
Self-citationRosas-Sánchez, G. U., Germán-Ponciano, L. J., Guillén-Ruiz, G., Cueto‐Escobedo, J., Limón-Vázquez, A. K., Rodríguez‐Landa, J. F., & Soria-Fregozo, C. (2024) · Biomedicines · doi:10.3390/biomedicines12122744 · Cited by 43
“…psilocybin, in male Wistar–Kyoto rats, which exhibit a depression-like phenotype, a single administration of psychedelic substances, such as psilocybin (1 mg/kg) and LSD (0.15 mg/kg), resulted in antidepressant-like effects in the FST that appear to last longer than the effects of ketamine [140].”
InfluentialAarrestad, I. K., Cameron, L. P., Fenton, E. M., Casey, A. B., Rijsketic, D. R., Patel, S. D., Sambyal, R., Johnson, S. B., Ly, C., Viswanathan, J., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02021-1 · Cited by 43
“To ascertain whether TBG directly engages 5-HT 2A Rs in vivo, we performed receptor occupancy studies in pigs using the positron emission tomography (PET) radiotracer [ 11 C]Cimbi-36.”
Takaba, R., Ibi, D., Yoshida, K., Hosomi, E., Kawase, R., Kitagawa, H., Goto, H., Achiwa, M., Mizutani, K., Maeda, K., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02778-x · Cited by 39
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Bradley, E., Sakai, K., Fernandes‐Osterhold, G., Szigeti, B., Ludwig, C., Ostrem, J. L., Tanner, C. M., Bock, M., Llerena, K., Finley, P. R., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02097-0 · Cited by 39
Serotonergic Psychedelics in Neural Plasticity
Lukasiewicz, K., Baker, J. J., Zuo, Y., & Lu, J. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.748359 · Cited by 31
Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Prouzeau, D., Conejero, I., Voyvodic, P. L., Bécamel, C., Abbar, M., & López‐Castromán, J. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01361-0 · Cited by 40
The role of serotonin neurotransmission in rapid antidepressant actions
Pehrson, A. L., Roberts, D., Khawaja, A., & McNair, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06098-5 · Cited by 37
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 37
“…psychedelics promote neuroplasticity by increasing the trafficking of AMPA-type glutamate receptors and elevating BDNF levels [51] (Figure 3) thus promoting the maintenance and strengthening of activity-dependent plasticity in active synapses and fostering long-term brain modifications [160].”
BackgroundMolecular targets of psychedelic‐induced plasticity
Jaster, A. M., Revenga, M. D. L. F., & González‐Maeso, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15536 · Cited by 36
Tiwari, P., Davoudian, P. A., Kapri, D., Vuruputuri, R. M., Karaba, L. A., Sharma, M., Zanni, G., Balakrishnan, A., Chaudhari, P. R., Pradhan, A., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.08.016 · Cited by 35
Duque, M., Chen, A., Hsu, E. T., Narayan, S., Rymbek, A., Begum, S., Saher, G., Cohen, A. E., Olson, D. E., Li, Y., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.11.011 · Cited by 34
“The 5-HT2A receptor agonist, TCB-2, 64 also suppressed futility-induced passivity (Figures 2K and 2L, right), similar to the effects of other psychedelics 65,66 in mammals.”
Animal Behavior in Psychedelic Research
Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000590 · Cited by 32
Psychedelic therapy in depression and substance use disorders
Korkmaz, N. D., Çıkrıkçılı, U., Akan, M., & Yücesan, E. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16421 · Cited by 32
“A single dose of LSD and psilocybin was found to produce antidepressant-like behaviour lasting up to 5 weeks in rat behavioural tests (Hibicke et al., 2020).”
A multi-institutional investigation of psilocybin’s effects on mouse behavior
Lu, O., White, K., Raymond, K. B., Liu, C. J., Klein, A. S., Green, N., Vaillancourt, S., Gallagher, A. J., Shindy, L., Li, A., et al. (2026) · Nature Neuroscience · doi:10.1101/2025.04.08.647810 · Cited by 34
Current and future directions of drug delivery for the treatment of mental illnesses
Brewster, P. R., Bari, S. M. I., Walker, G. M., & Werfel, T. A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114824 · Cited by 30
Wojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Maćkowiak, M., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010100 · Cited by 30
“Similarly to ketamine, psychedelics seem to induce synaptic plasticity and neurogenesis in preclinical models [16,17] while being devoid of the drawbacks of ketamine.”
BackgroundKolasa, M., Nikiforuk, A., Korlatowicz, A., Solich, J., Potasiewicz, A., Dziedzicka‐Wasylewska, M., Bugno, R., Hogendorf, A. S., Bojarski, A. J., & Faron‐Górecka, A. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06644-3 · Cited by 29
New Paradigms of Old Psychedelics in Schizophrenia
Mahmood, D., Alenezi, S. K., Anwar, M. J., Azam, F., Qureshi, K. A., & Jaremko, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050640 · Cited by 29
“, revealed that psychedelic compounds lowered depressive symptoms in a rodent model of depression suggesting that the therapeutic potential of classic psychedelics might be better than ketamine [64].”
BackgroundHibicke, M., & Nichols, C. D. (2022) · Scientific Reports · doi:10.1038/s41598-022-14165-2 · Cited by 29
Self-citationNikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.042 · Cited by 28
Hibicke, M., Kramer, H. M., & Nichols, C. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0012 · Cited by 29
“1,2 Psychedelics have been shown to have rapid persistent antidepressant and anxiolytic effects in humans from only one or two doses, 3–8 and antidepressant-like effects in rats 9–11 and fruit flies.”
InfluentialSelf-citationBedside to bench: the outlook for psychedelic research
Acero, V. P., Cribas, E. S., Browne, K. D., Rivellini, O. M., Burrell, J. C., O’Donnell, J. C., Das, S., & Cullen, D. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1240295 · Cited by 28
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 28
“Aligning with these results, Hibicke et al. (2020) found that psilocybin facilitates a period of behavioural flexibility, whereby rats that explored a non-home cage environment after psilocybin administration had reduced anxiety in a subsequent exploration of novel environments.”
Pharmacological and behavioural effects of tryptamines present in psilocybin‐containing mushrooms
Rakoczy, R. J., Runge, G. N., Sen, A. K., Sandoval, O., Wells, H. G., Nguyen, Q., Roberts, B., Sciortino, J. H., Gibbons, W. J., Friedberg, L. M., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16466 · Cited by 28
Rosas-Sánchez, G. U., German-Ponciano, L. J., Guillén-Ruiz, G., Cueto-Escobedo, J., Limón-Vázquez, A. K., Rodríguez-Landa, J. F., & Soria-Fregozo, C. (2024) · doi:10.20944/preprints202410.2591.v1 · Cited by 28
Preclinical models of treatment-resistant depression: challenges and perspectives
Kolasa, M., & Faron‐Górecka, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00542-9 · Cited by 27
“Although ketamine produces rapid antidepressant effects, long-term antidepressant effects are produced by a single administration of psilocybin [71].”
BackgroundInfluentialMolecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 27
“A recent study by Hibicke et al. [105] demonstrated the anxiolytic properties of psilocybin if the animals were repeatedly exposed to the novel environment.”
BackgroundErkizia-Santamaría, I., Horrillo, I., Martínez-Álvarez, N., Pérez-Martínez, D., Rivero, G., Erdozain, A. M., Meana, J. J., & Ortega, J. E. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03421-4 · Cited by 26
“It is reasonable to think that a closer time point would be more suitable for the evaluation of certain molecular pathways targeted by the drug, to unfold the molecular basis of the therapeutic action of psilocybin.”
Dworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 27
Rapid, biochemical tagging of cellular activity history in vivo
Zhang, R., Anguiano, M., Aarrestad, I. K., Lin, S., Chandra, J., Vadde, S. S., Olson, D. E., & Kim, C. K. (2024) · Nature Methods · doi:10.1038/s41592-024-02375-7 · Cited by 25
Werle, I., & Bertoglio, L. J. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105899 · Cited by 26
Viktorov, M., Wilkinson, M. P., Elston, V. C. E., Stone, M., & Robinson, E. S. J. (2022) · Brain and Neuroscience Advances · doi:10.1177/23982128221081645 · Cited by 25
“It is worth, however, noting findings from Hibicke et al. (2020) who reported a decreased FST immobility time in the Wistar– Kyoto rats following a 35-day pre-treatment period.”
BackgroundGlavonic, E., Mitić, M., & Adžić, M. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25017 · Cited by 24
“…can significantly relieve anxiety symptoms as evidenced by both clinical and preclinical studies (Davis et al., 2018, 2019; Griffiths et al., 2016; Hibicke et al., 2020; Ross et al., 2016; Winne et al., 2020), with DMT successfully abolishing preexisting anxiety- like behavior (Winne et al.,…”
BackgroundResultInfluentialInserra, A., Piot, A., Gregorio, D. D., & Gobbi, G. (2023) · CNS Drugs · doi:10.1007/s40263-023-01008-5 · Cited by 24
Armstrong, M., Castellanos, J. P., & Christie, D. (2024) · Frontiers in Pain Research · doi:10.3389/fpain.2024.1346053 · Cited by 24
New investigational agents for the treatment of major depressive disorder
Pochwat, B., Krupa, A. J., Siwek, M., & Szewczyk, B. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2113376 · Cited by 23
Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome
Buzzelli, V., Carbone, E., Manduca, A., Schiavi, S., Feo, A., Perederiy, J. V., Ambert, K. H., Hausman, M., & Trezza, V. (2023) · Psychopharmacology · doi:10.1007/s00213-022-06286-3 · Cited by 22
“Furthermore, Hibicke and colleagues demonstrated an antidepressant effect of psilocybin in Wistar rats (Hibicke et al. 2020), and a study by Mollinedo-Gajate and colleagues (in press) has shown that psilocybin rescues social alterations displayed by mice prenatally exposed to valproic acid (Mollinedo-Gajate et al.”
BackgroundResultInfluentialHarari, R., Chatterjee, I., Getselter, D., & Elliott, E. (2024) · iScience · doi:10.1016/j.isci.2024.109686 · Cited by 21
Pilc, A., Machaczka, A., Kawalec, P., Smith, J. L., & Witkin, J. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2111415 · Cited by 21
“Data from preclinical experiments indicate that classic psychedelics may have therapeutic efficacy (antidepressant-detecting models) which lasts for weeks and might be more persistent than that of ketamine [61].”
BackgroundConcurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner
Farinha‐Ferreira, M., Miranda‐Lourenço, C., Galipeau, C., Lenkei, Z., & Sebastião, A. M. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110280 · Cited by 20
Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin
Gattuso, J. J., Wilson, C., Li, S., Hannan, A. J., & Renoir, T. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177304 · Cited by 18
Pouyan, N., Khankahdani, Z. H., Sisi, F. Y., Lee, Y. L., Rosenblat, J. D., Teopiz, K. M., Lui, L. M. W., Subramaniapillai, M., Lin, K., Nasri, F., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00944-y · Cited by 18
“In contrast, three studies that investigated the effect of psilocybin on locomotor behavior in animal models demonstrated no effects of psilocybin on this feature [72, 75, 139].”
Psilocybin reduces grooming in the SAPAP3 knockout mouse model of compulsive behaviour
Gattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110202 · Cited by 17
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists
Sharp, T., & Ippolito, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70050 · Cited by 17
“…onset antidepressant action (see above) is supported by findings in animal models that the drugs also induce antidepressant-like behavioural effects after a single injection, and that these effects can persist (Cameron et al., 2023; Hibicke et al., 2020; Sekssaoui et al., 2024; Shao et al., 2021).”
Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters
Jahanabadi, S., Amiri, S., Karkeh-abadi, M., & Razmi, A. (2023) · Fitoterapia · doi:10.1016/j.fitote.2023.105620 · Cited by 16
Metadata
- Authors
- Hibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D.
- Affiliations
- Louisiana State University (US)
- Corresponding author
- Nichols, Charles D.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-05
- Volume
- 11
- Issue
- 6
- Pages
- 864-871
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W3010499243
- Cited by
- 205
- References
- 65
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 38 · 2023: 40 · 2022: 42 · 2021: 20 · 2020: 11
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Funders
- Eleusis PBC (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, LSD, ketamine, psychedelics, antidepressant effects, depression, subjective experience, rat model of depression, rapid-acting antidepressants
- MeSH terms
- Animals, Antidepressive Agents, Depression, Hallucinogens, Ketamine, Rodentia, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.